Jounce Therapeutics Inc  

(Public, NASDAQ:JNCE)   Watch this stock  
Find more results for JNCE
-0.18 (-0.74%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.01 - 24.85
52 week 11.05 - 29.29
Open 24.01
Vol / Avg. 144,492.00/338,777.00
Mkt cap 775.51M
P/E     -
Div/yield     -
EPS -0.17
Shares 32.25M
Beta     -
Inst. own 130%
Jan 10, 2018
Jounce Therapeutics Inc at JPMorgan Healthcare Conference
Dec 14, 2017
Jounce Therapeutics Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -22.59% -36.84%
Operating margin -24.27% -38.89%
EBITD margin - -33.66%
Return on average assets -5.01% -8.45%
Return on average equity -9.29% -
Employees 108 -
CDP Score - -


780 Memorial Dr
CAMBRIDGE, MA 02139-4613
United States - Map
+1-857-2593840 (Phone)
+1-617-8125345 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.

Officers and directors

Perry Karsen Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Richard Murray Ph.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
James P. Allison Ph.D. Co-Founder
Bio & Compensation  - Reuters
Thomas F. Gajewski M.D. Ph.D. Co-Founder
Bio & Compensation  - Reuters
Drew Pardoll M.D. Ph.D. Co-Founder
Bio & Compensation  - Reuters
Padmanee Sharma M.D. Ph.D. Co-Founder
Bio & Compensation  - Reuters
Kimberlee Cobleigh Drapkin CPA Chief Financial Officer, Treasurer
Age: 49
Bio & Compensation  - Reuters
Deborah Law Chief Scientific Officer
Bio & Compensation  - Reuters
Elizabeth G. Trehu M.D. Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Luis A. Diaz Jr. M.D. Director
Bio & Compensation  - Reuters